This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBioasis Technologies (107) 주식 개요Operates as a biopharmaceutical company. 자세히 보기107 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석최신 재무 보고서가 1년 이상 지났습니다.의미 있는 시가총액이 없습니다(€270K)주식은 유동성이 매우 낮습니다모든 위험 점검 보기107 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.00815.9% 고평가 내재 할인율Est. Revenue$PastFuture-5m4m2016201920222025202620282031Revenue CA$269.4kEarnings CA$49.0kAdvancedSet Fair ValueView all narrativesBioasis Technologies Inc. 경쟁사bioXXmedSymbol: XTRA:T5O0Market cap: €329.8kco.donSymbol: XTRA:CNWMarket cap: €6.5mMedigeneSymbol: XTRA:MDG1Market cap: €1.8m4SCSymbol: DB:VSCMarket cap: €1.1m가격 이력 및 성과Bioasis Technologies 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$0.00852주 최고가CA$0.01852주 최저가CA$0.0005베타01개월 변동0%3개월 변동1,500.00%1년 변동700.00%3년 변동-96.08%5년 변동-95.14%IPO 이후 변동-98.60%최근 뉴스 및 업데이트공시 • Jan 25Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI).Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) for $5.5 million on December 13, 2022. As per the terms of the transaction, MTPH shall issue 75,884,553 new ordinary shares at an exchange ratio of 0.9556 Ordinary Shares for every 1 Bioasis Share. A private placement equity financing of approximately $10 million that will be completed concurrently with Midatech’s acquisition of Bioasis. Upon completion of the Arrangement and the Midatech Financing, it is expected that the current Midatech securityholders, the current Bioasis securityholders and the Midatech Financing investor will own approximately 39.8%, 30.7% and 9.9% stake, respectively. The combination of Bioasis and Midatech will create a multi-asset rare and orphan disease company that will be renamed Biodexa Pharmaceuticals PLC (“Biodexa”). Post deal completion, Stephen Parker shall serve as non-executive chairman, Deborah Rathjen (currently Bioasis’ executive chair and Chief Executive Officer), Mario Saltarelli (currently a Bioasis director) and Simon Turton shall serve as non-executive directors and Stephen Stamp shall serve as Chief Executive Officer and director. Bioasis and Midatech shall pay a termination of $330,000 to the other party. Completion of the Arrangement is subject to the completion of the Midatech Financing and Midatech shareholder approval along with other closing conditions customary for transaction of this nature including, among other things, approval of the Arrangement by the Supreme Court of British Columbia, the TSX-V having approved the de-listing of the Bioasis Shares, Bioasis Shareholders shall not have exercised Dissent Rights in connection with the Arrangement with respect to more than 10% of the issued and outstanding Bioasis Shares and the approval of at least two-thirds of the votes cast by all Bioasis shareholders. The board of directors of Bioasis (the “Board”) has unanimously approved the Arrangement Agreement and resolved to recommend that Bioasis securityholders vote in favour of the Arrangement at the Bioasis Meeting. As of December 19, 2022, Midatech is no longer required to seek delisting from AIM following completion of the arrangement. The transaction is expected to close in the first quarter of 2023. The transaction is expected to close by the end of February 2023. The Arrangement is anticipated to be completed on or about February 8, 2023. Evans & Evans, Inc. acted as fairness opinion provider to Bioasis. Goodmans LLP and Lawson Lundell LLP are Bioasis’ Canadian legal advisors. Ladenburg Thalmann & Co. Inc. (“Ladenburg”) is Bioasis’ financial advisor. Pursuant to the terms of Ladenburg’s engagement by Bioasis, Ladenburg is entitled to receive a fee upon the completion of the Arrangement in the form of Midatech securities. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for Midatech. James Dance, Matthew Chandler and Rob Patrick of Strand Hanson Limited acted as financial advisors to Midatech. Andrew Thacker and James Pope of Turner Pope Investments (TPI) Ltd acted as brokers and The Bank of New York Mellon acted as depository bank and Neville Registrars Limited acted as transfer agent for Midatech. Brown Rudnick LLP, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Fasken Martineau DuMoulin LLP all acted as legal advisors while Mazars LLP acted as accountant to Midatech. Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI) on January 23, 2023. One of the conditions precedent to completion of the Arrangement was approval of the Arrangement and a number of related matters by the Midatech shareholders. Midatech has announced that its shareholders did not approve the Arrangement at the general meeting of Midatech shareholders held on January 23, 2023.공시 • Dec 22Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023.Reported Earnings • Jun 27Full year 2021 earnings released: EPS CA$0.01 (vs CA$0.065 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: CA$4.08m (up CA$3.47m from FY 2020). Net income: CA$698.4k (up CA$4.75m from FY 2020). Profit margin: 17% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Jan 30Revenue misses expectationsRevenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 11% compared to a 81% growth forecast for the Biotechs industry in Germany.Is New 90 Day High Low • Jan 13New 90-day high: €0.27The company is up 10.0% from its price of €0.25 on 14 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.35 per share.Reported Earnings • Oct 30First half earnings releasedOver the last 12 months the company has reported total losses of CA$493.7k, with losses narrowing by 87% from the prior year. Total revenue was CA$4.30m over the last 12 months, up 146% from the prior year.더 많은 업데이트 보기Recent updates공시 • Jan 25Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI).Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) for $5.5 million on December 13, 2022. As per the terms of the transaction, MTPH shall issue 75,884,553 new ordinary shares at an exchange ratio of 0.9556 Ordinary Shares for every 1 Bioasis Share. A private placement equity financing of approximately $10 million that will be completed concurrently with Midatech’s acquisition of Bioasis. Upon completion of the Arrangement and the Midatech Financing, it is expected that the current Midatech securityholders, the current Bioasis securityholders and the Midatech Financing investor will own approximately 39.8%, 30.7% and 9.9% stake, respectively. The combination of Bioasis and Midatech will create a multi-asset rare and orphan disease company that will be renamed Biodexa Pharmaceuticals PLC (“Biodexa”). Post deal completion, Stephen Parker shall serve as non-executive chairman, Deborah Rathjen (currently Bioasis’ executive chair and Chief Executive Officer), Mario Saltarelli (currently a Bioasis director) and Simon Turton shall serve as non-executive directors and Stephen Stamp shall serve as Chief Executive Officer and director. Bioasis and Midatech shall pay a termination of $330,000 to the other party. Completion of the Arrangement is subject to the completion of the Midatech Financing and Midatech shareholder approval along with other closing conditions customary for transaction of this nature including, among other things, approval of the Arrangement by the Supreme Court of British Columbia, the TSX-V having approved the de-listing of the Bioasis Shares, Bioasis Shareholders shall not have exercised Dissent Rights in connection with the Arrangement with respect to more than 10% of the issued and outstanding Bioasis Shares and the approval of at least two-thirds of the votes cast by all Bioasis shareholders. The board of directors of Bioasis (the “Board”) has unanimously approved the Arrangement Agreement and resolved to recommend that Bioasis securityholders vote in favour of the Arrangement at the Bioasis Meeting. As of December 19, 2022, Midatech is no longer required to seek delisting from AIM following completion of the arrangement. The transaction is expected to close in the first quarter of 2023. The transaction is expected to close by the end of February 2023. The Arrangement is anticipated to be completed on or about February 8, 2023. Evans & Evans, Inc. acted as fairness opinion provider to Bioasis. Goodmans LLP and Lawson Lundell LLP are Bioasis’ Canadian legal advisors. Ladenburg Thalmann & Co. Inc. (“Ladenburg”) is Bioasis’ financial advisor. Pursuant to the terms of Ladenburg’s engagement by Bioasis, Ladenburg is entitled to receive a fee upon the completion of the Arrangement in the form of Midatech securities. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for Midatech. James Dance, Matthew Chandler and Rob Patrick of Strand Hanson Limited acted as financial advisors to Midatech. Andrew Thacker and James Pope of Turner Pope Investments (TPI) Ltd acted as brokers and The Bank of New York Mellon acted as depository bank and Neville Registrars Limited acted as transfer agent for Midatech. Brown Rudnick LLP, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Fasken Martineau DuMoulin LLP all acted as legal advisors while Mazars LLP acted as accountant to Midatech. Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI) on January 23, 2023. One of the conditions precedent to completion of the Arrangement was approval of the Arrangement and a number of related matters by the Midatech shareholders. Midatech has announced that its shareholders did not approve the Arrangement at the general meeting of Midatech shareholders held on January 23, 2023.공시 • Dec 22Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023.Reported Earnings • Jun 27Full year 2021 earnings released: EPS CA$0.01 (vs CA$0.065 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: CA$4.08m (up CA$3.47m from FY 2020). Net income: CA$698.4k (up CA$4.75m from FY 2020). Profit margin: 17% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Jan 30Revenue misses expectationsRevenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 11% compared to a 81% growth forecast for the Biotechs industry in Germany.Is New 90 Day High Low • Jan 13New 90-day high: €0.27The company is up 10.0% from its price of €0.25 on 14 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.35 per share.Reported Earnings • Oct 30First half earnings releasedOver the last 12 months the company has reported total losses of CA$493.7k, with losses narrowing by 87% from the prior year. Total revenue was CA$4.30m over the last 12 months, up 146% from the prior year.Analyst Estimate Surprise Post Earnings • Oct 30Second-quarter earnings released: Revenue beats expectationsSecond-quarter revenue exceeded analyst estimates by 1,531% at CA$4.08m. Revenue is expected to shrink by 33% over the next year, compared to a 273% growth forecast for the Biotechs industry in Germany.주주 수익률107DE BiotechsDE 시장7D0%0.9%3.2%1Y700.0%-12.2%2.5%전체 주주 수익률 보기수익률 대 산업: 107은 지난 1년 동안 -12.2%의 수익을 기록한 German Biotechs 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: 107은 지난 1년 동안 2.5%를 기록한 German 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is 107's price volatile compared to industry and market?107 volatility107 Average Weekly Movementn/aBiotechs Industry Average Movement8.7%Market Average Movement6.1%10% most volatile stocks in DE Market13.6%10% least volatile stocks in DE Market2.7%안정적인 주가: 107의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine 107의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트n/an/aDeborah Rathjenwww.bioasis.us더 보기Bioasis Technologies Inc. 기초 지표 요약Bioasis Technologies의 순이익과 매출은 시가총액과 어떻게 비교됩니까?107 기초 통계시가총액€269.57k순이익 (TTM)-€1.95m매출 (TTM)€182.88k0.0x주가매출비율(P/S)0.0x주가수익비율(P/E)107는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표107 손익계산서 (TTM)매출CA$269.38k매출원가CA$968.85k총이익-CA$699.47k기타 비용CA$2.18m순이익-CA$2.88m최근 보고된 실적Nov 30, 2022다음 실적 발표일해당 없음주당순이익(EPS)0총이익률0.00%순이익률0.00%부채/자본 비율0.0%107의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/06/18 01:39종가2024/03/22 00:00수익2022/11/30연간 수익2022/02/28데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bioasis Technologies Inc.는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Nathaniel CallowayEdison Investment ResearchWilliam GregozeskiGreenridge Global LLCJohn VandermostenZacks Small-Cap Research
공시 • Jan 25Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI).Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) for $5.5 million on December 13, 2022. As per the terms of the transaction, MTPH shall issue 75,884,553 new ordinary shares at an exchange ratio of 0.9556 Ordinary Shares for every 1 Bioasis Share. A private placement equity financing of approximately $10 million that will be completed concurrently with Midatech’s acquisition of Bioasis. Upon completion of the Arrangement and the Midatech Financing, it is expected that the current Midatech securityholders, the current Bioasis securityholders and the Midatech Financing investor will own approximately 39.8%, 30.7% and 9.9% stake, respectively. The combination of Bioasis and Midatech will create a multi-asset rare and orphan disease company that will be renamed Biodexa Pharmaceuticals PLC (“Biodexa”). Post deal completion, Stephen Parker shall serve as non-executive chairman, Deborah Rathjen (currently Bioasis’ executive chair and Chief Executive Officer), Mario Saltarelli (currently a Bioasis director) and Simon Turton shall serve as non-executive directors and Stephen Stamp shall serve as Chief Executive Officer and director. Bioasis and Midatech shall pay a termination of $330,000 to the other party. Completion of the Arrangement is subject to the completion of the Midatech Financing and Midatech shareholder approval along with other closing conditions customary for transaction of this nature including, among other things, approval of the Arrangement by the Supreme Court of British Columbia, the TSX-V having approved the de-listing of the Bioasis Shares, Bioasis Shareholders shall not have exercised Dissent Rights in connection with the Arrangement with respect to more than 10% of the issued and outstanding Bioasis Shares and the approval of at least two-thirds of the votes cast by all Bioasis shareholders. The board of directors of Bioasis (the “Board”) has unanimously approved the Arrangement Agreement and resolved to recommend that Bioasis securityholders vote in favour of the Arrangement at the Bioasis Meeting. As of December 19, 2022, Midatech is no longer required to seek delisting from AIM following completion of the arrangement. The transaction is expected to close in the first quarter of 2023. The transaction is expected to close by the end of February 2023. The Arrangement is anticipated to be completed on or about February 8, 2023. Evans & Evans, Inc. acted as fairness opinion provider to Bioasis. Goodmans LLP and Lawson Lundell LLP are Bioasis’ Canadian legal advisors. Ladenburg Thalmann & Co. Inc. (“Ladenburg”) is Bioasis’ financial advisor. Pursuant to the terms of Ladenburg’s engagement by Bioasis, Ladenburg is entitled to receive a fee upon the completion of the Arrangement in the form of Midatech securities. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for Midatech. James Dance, Matthew Chandler and Rob Patrick of Strand Hanson Limited acted as financial advisors to Midatech. Andrew Thacker and James Pope of Turner Pope Investments (TPI) Ltd acted as brokers and The Bank of New York Mellon acted as depository bank and Neville Registrars Limited acted as transfer agent for Midatech. Brown Rudnick LLP, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Fasken Martineau DuMoulin LLP all acted as legal advisors while Mazars LLP acted as accountant to Midatech. Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI) on January 23, 2023. One of the conditions precedent to completion of the Arrangement was approval of the Arrangement and a number of related matters by the Midatech shareholders. Midatech has announced that its shareholders did not approve the Arrangement at the general meeting of Midatech shareholders held on January 23, 2023.
공시 • Dec 22Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023.
Reported Earnings • Jun 27Full year 2021 earnings released: EPS CA$0.01 (vs CA$0.065 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: CA$4.08m (up CA$3.47m from FY 2020). Net income: CA$698.4k (up CA$4.75m from FY 2020). Profit margin: 17% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Jan 30Revenue misses expectationsRevenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 11% compared to a 81% growth forecast for the Biotechs industry in Germany.
Is New 90 Day High Low • Jan 13New 90-day high: €0.27The company is up 10.0% from its price of €0.25 on 14 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.35 per share.
Reported Earnings • Oct 30First half earnings releasedOver the last 12 months the company has reported total losses of CA$493.7k, with losses narrowing by 87% from the prior year. Total revenue was CA$4.30m over the last 12 months, up 146% from the prior year.
공시 • Jan 25Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI).Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) for $5.5 million on December 13, 2022. As per the terms of the transaction, MTPH shall issue 75,884,553 new ordinary shares at an exchange ratio of 0.9556 Ordinary Shares for every 1 Bioasis Share. A private placement equity financing of approximately $10 million that will be completed concurrently with Midatech’s acquisition of Bioasis. Upon completion of the Arrangement and the Midatech Financing, it is expected that the current Midatech securityholders, the current Bioasis securityholders and the Midatech Financing investor will own approximately 39.8%, 30.7% and 9.9% stake, respectively. The combination of Bioasis and Midatech will create a multi-asset rare and orphan disease company that will be renamed Biodexa Pharmaceuticals PLC (“Biodexa”). Post deal completion, Stephen Parker shall serve as non-executive chairman, Deborah Rathjen (currently Bioasis’ executive chair and Chief Executive Officer), Mario Saltarelli (currently a Bioasis director) and Simon Turton shall serve as non-executive directors and Stephen Stamp shall serve as Chief Executive Officer and director. Bioasis and Midatech shall pay a termination of $330,000 to the other party. Completion of the Arrangement is subject to the completion of the Midatech Financing and Midatech shareholder approval along with other closing conditions customary for transaction of this nature including, among other things, approval of the Arrangement by the Supreme Court of British Columbia, the TSX-V having approved the de-listing of the Bioasis Shares, Bioasis Shareholders shall not have exercised Dissent Rights in connection with the Arrangement with respect to more than 10% of the issued and outstanding Bioasis Shares and the approval of at least two-thirds of the votes cast by all Bioasis shareholders. The board of directors of Bioasis (the “Board”) has unanimously approved the Arrangement Agreement and resolved to recommend that Bioasis securityholders vote in favour of the Arrangement at the Bioasis Meeting. As of December 19, 2022, Midatech is no longer required to seek delisting from AIM following completion of the arrangement. The transaction is expected to close in the first quarter of 2023. The transaction is expected to close by the end of February 2023. The Arrangement is anticipated to be completed on or about February 8, 2023. Evans & Evans, Inc. acted as fairness opinion provider to Bioasis. Goodmans LLP and Lawson Lundell LLP are Bioasis’ Canadian legal advisors. Ladenburg Thalmann & Co. Inc. (“Ladenburg”) is Bioasis’ financial advisor. Pursuant to the terms of Ladenburg’s engagement by Bioasis, Ladenburg is entitled to receive a fee upon the completion of the Arrangement in the form of Midatech securities. Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for Midatech. James Dance, Matthew Chandler and Rob Patrick of Strand Hanson Limited acted as financial advisors to Midatech. Andrew Thacker and James Pope of Turner Pope Investments (TPI) Ltd acted as brokers and The Bank of New York Mellon acted as depository bank and Neville Registrars Limited acted as transfer agent for Midatech. Brown Rudnick LLP, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Fasken Martineau DuMoulin LLP all acted as legal advisors while Mazars LLP acted as accountant to Midatech. Midatech Pharma plc (AIM:MTPH) cancelled the acquisition of Bioasis Technologies Inc. (TSXV:BTI) on January 23, 2023. One of the conditions precedent to completion of the Arrangement was approval of the Arrangement and a number of related matters by the Midatech shareholders. Midatech has announced that its shareholders did not approve the Arrangement at the general meeting of Midatech shareholders held on January 23, 2023.
공시 • Dec 22Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023Bioasis Technologies Inc., Annual General Meeting, Feb 03, 2023.
Reported Earnings • Jun 27Full year 2021 earnings released: EPS CA$0.01 (vs CA$0.065 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: CA$4.08m (up CA$3.47m from FY 2020). Net income: CA$698.4k (up CA$4.75m from FY 2020). Profit margin: 17% (up from net loss in FY 2020). Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Jan 30Revenue misses expectationsRevenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 11% compared to a 81% growth forecast for the Biotechs industry in Germany.
Is New 90 Day High Low • Jan 13New 90-day high: €0.27The company is up 10.0% from its price of €0.25 on 14 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.35 per share.
Reported Earnings • Oct 30First half earnings releasedOver the last 12 months the company has reported total losses of CA$493.7k, with losses narrowing by 87% from the prior year. Total revenue was CA$4.30m over the last 12 months, up 146% from the prior year.
Analyst Estimate Surprise Post Earnings • Oct 30Second-quarter earnings released: Revenue beats expectationsSecond-quarter revenue exceeded analyst estimates by 1,531% at CA$4.08m. Revenue is expected to shrink by 33% over the next year, compared to a 273% growth forecast for the Biotechs industry in Germany.
